Humira Drug Market Report 2026

Humira Drug Market Overview

• Humira Drug market size has reached to $10.33 billion in 2025 • Expected to grow to $15.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.3% • Growth Driver: Growing Incidence Of Autoimmune Diseases Fuels Demand For Humira Drug • Market Trend: Boehringer Ingelheim Introduces Cost-Effective Biosimilar For Humira Drugs • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Humira Drug Market?

Humira drug, or adalimumab, refers to an injection prescribed to treat rheumatoid arthritis and other conditions. These drugs are used to reduce the pain and swelling caused by several types of arthritis. The main types of humira drugs are humira syringes and humira pens. Humira syringe refers to a type of treatment that is used to treat progressive rheumatoid arthritis. The various applications include ankylosing spondylitis, rheumatoid arthritis, Crohn's disease, and others, which are used by various end-users such as hospitals, specialty clinics, and others.

What Is The Humira Drug Market Growth Forecast?

The humira drug market size is expected to see strong growth in the next few years. It will grow to $15.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to expansion of biosimilars, increasing patient preference for self-administration, rising telemedicine adoption, growing geriatric population, expansion in emerging markets, innovation in pre-filled pen delivery, increasing government support for biologics, integration with digital health platforms, personalized medicine trends, improved insurance coverage. Major trends in the forecast period include personalized arthritis treatment, biologic therapy adoption, home-based injection solutions, combination therapy approaches, telemedicine integration.

Global Humira Drug Market Segmentation

1) By Type: Humira Syringe, Humira Pen 2) By Application: Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn's Disease, Other Applications 3) By End-Users: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Humira Syringe: Pre-Filled Syringe, Disposable Syringe 2) By Humira Pen: Auto-Injector Pen, Pre-Filled Injection Pen

What Is The Driver Of The Humira Drug Market?

A rise in the incidence rate of autoimmune disease is expected to propel the growth of the humira drug market going forward. Autoimmune disease refers to a type of disease in which the body's immune system attacks and destroys healthy tissues and cells in the body. Humira drug is used to treat pain and inflammation caused by various autoimmune diseases, as a result, the rise in the incidence rate of autoimmune diseases increases the demand for humira drug. For instance, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, by 2025, approximately 562,378 Australians are living with rheumatoid arthritis (RA), accounting for 14% of the total arthritis population. Therefore, the rise in the incidence rate of autoimmune disease will drive the HUMIRA drug industry.

Key Players In The Global Humira Drug Market

Major companies operating in the humira drug market are AbbVie Inc., Amgen Inc., Sandoz International GmbH, Viatris Inc., Samsung Bioepis Co Ltd., Coherus BioSciences Inc., Celltrion Healthcare Co Ltd., Alvotech Holdings S.A, Biocad Biopharmaceutical Company, Fujifilm Kyowa Kirin Biologics Co Ltd, Alteogen Inc, Bio-Thera Solutions Ltd, Momenta Pharmaceuticals Inc, Innovent Biologics Inc, CinnaGen Co, Hetero Healthcare Ltd, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals Ltd, Cadila Pharmaceuticals Ltd, Mochida Pharmaceutical Co Ltd

Global Humira Drug Market Trends and Insights

Major companies operating in the himra drug market are focusing on developing biosimilars for humira drugs. Companies are focusing on increasing cost effectiveness of humira drugs by manufacturing specialty biosimilars suited for humira drugs. For instance, in October 2023, Boehringer Ingelheim a Germany-based pharmaceutical company launched biosimilar of Humira. The only close copies of Humira approved by the US Food and Drug Administration to be interchangeable are those made by Boehringer, which can be used in place of the original without a prescription.

What Are Latest Mergers And Acquisitions In The Humira Drug Market?

In August 2023, CVS Health Corporation, a US-based pharmacy company partnered with Sandoz Group AG. This partnership aims to create a nearly identical drug that will be produced at a much cheaper cost than the popular arthritis treatment Humira. The goal of this partnership is to help CVS Health better position itself in the biosimilars market, which is predicted to reach $100 billion in sales over the next six years. As part of the partnership, Cordavis, a new subsidiary of Novartis, will be established. Its primary focus will be on ensuring the supply of novel biosimilar medications. Sandoz Group AG is a Switzerland-based pharmaceuticals company.

Regional Insights

North America was the largest region in the humira drug market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Humira Drug Market?

The humira drug market consists of sales of single-dose pen, a single-dose prefilled syringe, and a single-dose vial of liquid solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Humira Drug Market Report 2026?

The humira drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the humira drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.